Clinical Pharmacology of Antibiotics

被引:117
作者
Eyler, Rachel F. [1 ,2 ]
Shvets, Kristina [2 ]
机构
[1] Univ Connecticut, Sch Pharm, Dept Pharm Practice, Unit 3092,69 North Eagleville Rd, Storrs, CT 06269 USA
[2] Yale New Haven Med Ctr, Dept Pharm Serv, 20 York St, New Haven, CT 06504 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2019年 / 14卷 / 07期
关键词
chronic renal disease; end-stage renal disease; antibiotics; pharmacology; hemodialysis; pharmacokinetics; pharmacodynamics; renal dialysis; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Lactams; Protein Binding; Kidney Failure; Chronic; Microbial Sensitivity Tests; Renal Insufficiency; Metabolic Clearance Rate; TRIMETHOPRIM-SULFAMETHOXAZOLE; RENAL IMPAIRMENT; PHARMACOKINETICS; PHARMACODYNAMICS; INFECTIONS; EXPERIENCE; AGENTS; COTRIMOXAZOLE; ORITAVANCIN; DALBAVANCIN;
D O I
10.2215/CJN.08140718
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Antimicrobial pharmacology and its effect on prescribing is quite complex. Selecting an antibiotic that will optimally treat an infection while minimizing adverse effects and the development of resistance is only the first step, as one must also consider the patient's individual pharmacokinetic alterations and the pharmacodynamic properties of the drug when prescribing it as well. Patients with CKD may have alterations in their protein binding, volumes of distribution, kidney clearance, and nonrenal clearance that necessitates antibiotic dose adjustments to prevent the development of toxicity. Knowledge of a drug's pharmacodynamics, defined as the relationship between drug exposure and antibacterial efficacy, provides some guidance regarding the optimal way to make dose adjustments. Different pharmacodynamic goals, such as maximizing the time that free (unbound) drug concentrations spend above the minimum inhibitory concentration (MIC) for time dependent drugs (e.g., beta-lactams) or maximizing the free peak-to-MIC ratio for concentration-dependent antibiotics (e.g., aminoglycosides), require different adjustment strategies; for instance, decreasing the dose while maintaining normal dosing frequency or giving normal (or even larger) doses less frequently, respectively. Patients receiving hemodialysis have other important prescribing considerations as well. The nephrologist or patient may prefer to receive antibiotics that can be administered intravenously toward the end of a dialysis session. Additionally, newer dialysis technologies and filters can increase drug removal more than originally reported. This review will discuss the place in therapy, mechanism of action, pharmacokinetic, pharmacodynamic, and other pharmacologic considerations encountered when prescribing commonly used antibiotics in patients with chronic kidney disease or ESKD.
引用
收藏
页码:1080 / 1090
页数:11
相关论文
共 65 条
[1]   The Spectrum of Infections in Catheter-Dependent Hemodialysis Patients [J].
Al-Solaiman, Yaser ;
Estrada, Erin ;
Allon, Michael .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (09) :2247-2252
[2]   Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole [J].
Alappan, R ;
Perazella, MA ;
Buller, GK .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (03) :316-320
[3]  
[Anonymous], 2016, FDA DRUG SAF COMM FD
[4]  
Aronoff G.R., 2007, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, V5th
[5]   Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease [J].
Barriere, Steven L. ;
Farrell, David J. ;
Rhomberg, Paul R. ;
Jones, Ronald N. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2014, 80 (04) :327-329
[6]   DRUG PRESCRIBING IN RENAL-FAILURE - DOSING GUIDELINES FOR ADULTS [J].
BENNETT, WM ;
ARONOFF, GR ;
MORRISON, G ;
GOLPER, TA ;
PULLIAM, J ;
WOLFSON, M ;
SINGER, I .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1983, 3 (03) :155-193
[7]   Musculoskeletal Safety Outcomes of Patients Receiving Daptomycin with HMG-CoA Reductase Inhibitors [J].
Bland, Christopher M. ;
Bookstaver, Brandon ;
Lu, Kevin ;
Dunn, Brianne L. ;
Rumley, Kathey Fulton .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (10) :5726-5731
[8]   Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients [J].
Britt, Nicholas S. ;
Tirmizi, Samad ;
Ritchie, David J. ;
Topal, Jeffrey E. ;
McManus, Dayna ;
Nizet, Victor ;
Casabar, Ed ;
Sakoulas, George .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (03) :764-767
[9]   Cotrimoxazole - optimal dosing in the critically ill [J].
Brown, Glen R. .
ANNALS OF INTENSIVE CARE, 2014, 4
[10]  
Butterfield JM, 2013, ANTIMICROB AGENTS CH, V57, P864, DOI [10.1128/AAC.02000-12, 10.1128/AAC.00539-13]